Anastrozole versus tamoxifen treatment in postmenopausal women with endocrine-responsive breast cancer and tamoxifen-induced endometrial pathology

• Published in: Clinical cancer research 2006-02, Vol.12 (4), p.1245-1250
• Main Authors: GERBER, Bernd, KRAUSE, Annette, REIMER, Toralf, MYLONAS, Ionas, MAKOVITZKY, Josef, KUNDT, Gunther, JANNI, Wolfgang
• Format: Article
• Language: English
• Subjects: Aged; Antineoplastic agents; Antineoplastic Agents, Hormonal - adverse effects; Antineoplastic Agents, Hormonal - therapeutic use; Biological and medical sciences; Breast Neoplasms - drug therapy; Dilatation and Curettage; Endometrium - diagnostic imaging; Endometrium - drug effects; Endometrium - pathology; Female; Gynecology. Andrology. Obstetrics; Humans; Hysteroscopy; Mammary gland diseases; Medical sciences; Middle Aged; Nitriles - adverse effects; Nitriles - therapeutic use; Pharmacology. Drug treatments; Postmenopause; Tamoxifen - adverse effects; Tamoxifen - therapeutic use; Triazoles - adverse effects; Triazoles - therapeutic use; Tumors; Ultrasonography; Uterine Hemorrhage - chemically induced; Uterine Hemorrhage - diagnosis; Uterine Hemorrhage - therapy
• ISSN: 1078-0432; 1557-3265
• DOI: 10.1158/1078-0432.CCR-05-0225

PURPOSE: To investigate the effect of switching from adjuvant tamoxifen to anastrozole (Arimidex) treatment in postmenopausal women with endocrine-responsive breast cancer and histologically proven tamoxifen-induced benign endometrial pathology. EXPERIMENTAL DESIGN: Two hundred twenty-six postmenopausal women who had received adjuvant tamoxifen 20 mg/d (> or =12 months, < or =48 months) and developed abnormal vaginal bleeding and/or an asymptomatic endometrial thickness >10 mm [measured by transvaginal ultrasound (TVUS)] were subjected to hysteroscopy and dilation and curettage (D&C). Thereafter, 171 patients were randomized in a phase III study to continue tamoxifen treatment (n = 88) or switch to anastrozole 1 mg/d (n = 83). Patients were monitored for < or =42 months using TVUS at 6-monthly intervals. RESULTS: At study entry, there were no significant differences in vaginal bleeding, endometrial thickness, and histologic findings between the two treatment groups. Throughout the treatment period, there was no significant difference in recurrent vaginal bleeding between groups [anastrozole, 4 of 83 (4.8%); tamoxifen, 9 of 88 (10.2%); P = 0.18]. Six months after randomization, the mean endometrial thickness for patients who switched to anastrozole was significantly reduced compared with those who continued tamoxifen treatment (P < 0.0001). Significantly fewer anastrozole patients required a repeat hysteroscopy and D&C compared with those on tamoxifen [4 of 83 (4.8%) and 29 of 88 (33.0%), respectively; P < 0.0001]. Repeat hysteroscopy and D&C revealed endometrial atrophy in all 4 cases in the anastrozole group and 14 polyps, 8 hyperplasias, and 7 atrophies in the tamoxifen group. CONCLUSIONS: Switching from tamoxifen to anastrozole treatment significantly reduced the need for a second hysteroscopy and D&C due to recurrent vaginal bleeding or thickening of the endometrium in postmenopausal breast cancer patients with tamoxifen-induced endometrial abnormalities.